ONO-7475 is primarily investigated for its potential therapeutic applications in cancer treatment. It functions as an inhibitor of AXL and MER tyrosine kinases, which are often overexpressed in various cancers and contribute to tumor growth, metastasis, and resistance to chemotherapy. By targeting these kinases, ONO-7475 aims to disrupt signaling pathways that promote cancer progression, making it a promising candidate for combination therapies with existing anticancer drugs. Additionally, its role in modulating the tumor microenvironment and enhancing immune responses is being explored, potentially improving outcomes in patients with resistant or advanced cancers. Research is ongoing to evaluate its efficacy and safety in clinical settings.